Genmab | GEN - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Almirall EUR 30.32M 22M 2025-12
Amarin USD -852K 7.26M 2025-12
Amgen USD 2.08B 570M 2026-03
argenx SE USD 426M 22.71M 2026-03
AstraZeneca USD 4.81B 894M 2026-06
Bayer EUR 321M 2.67B 2026-06
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Demant DKK 1.64B 173M 2025-12
Exelixis USD 262.68M 5.01M 2026-06
Fresenius Medical Care EUR 383M 43M 2026-06
Genmab DKK 295M 221M 2026-06
GlaxoSmithKline GBP 2.68B 532M 2026-06
GN Store Nord DKK -281M 280M 2026-06
GRIFOLS EUR 247M 135M 2026-06
Hikma Pharmaceutical USD 147.5M 3.5M 2025-06
Insmed USD -11.37M 150.72M 2026-06
Lakefront Biotherapeutics EUR 13.96M 769.2M 2026-03
Lonza CHF 624M 197M 2024-12
Merck EUR 869M 468M 2026-03
Novartis USD 4.27B 430M 2026-06
Regeneron Pharmaceuticals USD 1.53B 696.6M 2026-06
Roche Holding CHF 11.17B 6.38B 2026-06
Sanofi EUR 837M 1.17B 2026-06
UCB EUR 789M 427M 2025-06